Agent
Lipoprotein apheresis
Status Approved and reimbursed for Lp(a) hyperlipoproteinaemia with progressive ASCVD in Germany since 2008; FDA indication in FH
Weekly or biweekly extracorporeal removal of apoB-containing lipoproteins lowers Lp(a) by 60 to 70 percent per session and, in the German Pro(a)LiFe cohort, cut annual cardiovascular event rates from 0.41 to 0.09 (Circulation 2013), sustained over 5 and 12 years (ATVB 2016, Atherosclerosis 2025). Uncontrolled evidence, but for fifteen years the only effective therapy. Lp(a)FRONTIERS APHERESIS (EHJ 2026) showed pelacarsen can replace it.
Page updated 17 August 2026.